Taher AT - Search Results

1

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Taher AT, et al. Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25. Eur J Haematol. 2014. PMID: 24460655 Free PMC article. Clinical Trial.

2

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.

Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Mourad FH, et al. Br J Haematol. 2003 Apr;121(1):187-9. doi: 10.1046/j.1365-2141.2003.04240.x. Br J Haematol. 2003. PMID: 12670352 Free article. Clinical Trial.

3

Chronic hepatitis C associated with Coombs-positive hemolytic anemia.

Elhajj II, Sharara AI, Taher AT. Elhajj II, et al. Among authors: taher at. Hematol J. 2004;5(4):364-6. doi: 10.1038/sj.thj.6200400. Hematol J. 2004. PMID: 15297855

4

Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.

Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, Sharara AI. Inati A, et al. Br J Haematol. 2005 Aug;130(4):644-6. doi: 10.1111/j.1365-2141.2005.05645.x. Br J Haematol. 2005. PMID: 16098081 Free article. Clinical Trial.

5

Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study.

Taher A, Sheikh-Taha M, Sharara A, Inati A, Koussa S, Ellis G, Dhillon AP, Hoffbrand AV. Taher A, et al. Acta Haematol. 2005;114(3):146-9. doi: 10.1159/000087888. Acta Haematol. 2005. PMID: 16227677

6

Thalassemia intermedia: revisited.

Taher A, Isma'eel H, Cappellini MD. Taher A, et al. Blood Cells Mol Dis. 2006 Jul-Aug;37(1):12-20. doi: 10.1016/j.bcmd.2006.04.005. Epub 2006 Jun 5. Blood Cells Mol Dis. 2006. PMID: 16737833 Review.

7

Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.

Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT. Otrock ZK, et al. Among authors: taher at. Ann Hematol. 2006 Sep;85(9):605-9. doi: 10.1007/s00277-006-0136-y. Epub 2006 Jul 8. Ann Hematol. 2006. PMID: 16830143 Clinical Trial.

8

Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran.

Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. Taher A, et al. Thromb Haemost. 2006 Oct;96(4):488-91. Thromb Haemost. 2006. PMID: 17003927

9

Stroke in thalassemia: a dilemma.

Taher A, Mehio G, Isma'eel H, Cappellini MD. Taher A, et al. Am J Hematol. 2008 Apr;83(4):343. doi: 10.1002/ajh.21117. Am J Hematol. 2008. PMID: 18183611 Free article. No abstract available.

10

Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood.

Musallam K, Cappellini MD, Taher A. Musallam K, et al. Pediatrics. 2008 May;121(5):e1426-9. doi: 10.1542/peds.2007-1944. Pediatrics. 2008. PMID: 18450884

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

519 results

Search Page

Filters